A Dose-Ranging Study of IPH2201 in Patients With Gynecologic Malignancies
Phase of Trial: Phase I/II
Latest Information Update: 15 Nov 2019
Price : $35 *
At a glance
- Drugs Monalizumab (Primary)
- Indications Adenocarcinoma; Carcinoma; Cervical cancer; Endometrial cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer; Squamous cell cancer
- Focus Adverse reactions
- 12 Nov 2019 Status changed from active, no longer recruiting to completed.
- 07 Aug 2019 Planned End Date changed from 30 Jun 2019 to 31 Dec 2019.
- 15 Jul 2019 Results (n=58) published in the Clinical Cancer Research.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History